Austin, Texas, January 21, 2026 — Natera, a global leader in cell-free DNA and precision medicine, announced the peer-reviewed publication of a clinical validation study for its Latitude™ tissue-free molecular residual disease (tfMRD) assay in colorectal cancer (CRC). Published in npj Precision Oncology, the study demonstrates high sensitivity, specificity, and strong prognostic and predictive performance, supporting submission to the CMS Molecular Diagnostics Services Program (MolDX) and establishing a clear pathway toward reimbursement in CRC.
Science Significance
Scientifically, the Latitude™ validation represents a major advance in tumor-agnostic, methylation-based MRD detection. The study analyzed 1,230 longitudinal timepoints from 195 patients enrolled in the GALAXY clinical trial—one of the largest tfMRD datasets in resectable CRC to date. Latitude™ achieved 84.4% longitudinal sensitivity, detecting recurrence a median of 4.6 months earlier than radiographic imaging, and 97.2% sample-level specificity, underscoring its ability to reliably distinguish true disease signals from background noise. Importantly, MRD positivity was associated with significantly worse outcomes, validating the assay’s role as a robust biomarker of residual disease and recurrence risk.
Regulatory Significance
From a regulatory perspective, the publication provides the clinical evidence foundation required for MolDX submission, a critical step toward Medicare coverage in the United States. High analytical and clinical performance metrics—combined with rigorous trial design—align with CMS expectations for clinical utility, actionability, and reliability in advanced diagnostics. The data also reinforce Latitude™ as a complementary option to tumor-informed assays when tissue is unavailable, expanding regulatory-acceptable testing pathways and supporting broader adoption across real-world clinical settings.
Business Significance
Advertisement
Commercially, the validation strengthens Natera’s position in the rapidly growing MRD diagnostics market. Latitude™ addresses a key unmet need by enabling tissue-free MRD testing, reducing dependency on archived tumor samples and streamlining clinical workflows. The assay complements Natera’s personalized Signatera™ test, creating a portfolio approach that broadens market reach and clinician choice. With MolDX submission enabled by this dataset and additional cancer indications in development for 2026, Latitude™ is poised to drive growth across oncology practices seeking scalable, high-performance MRD solutions.
Patients’ Significance
For patients with colorectal cancer, the implications are substantial. Earlier and more accurate MRD detection can inform post-surgical risk stratification, guide surveillance intensity, and support timely therapeutic decisions. The study showed that MRD-positive patients derived significant benefit from adjuvant chemotherapy, while MRD-negative patients did not—highlighting the test’s potential to personalize treatment, avoid unnecessary toxicity, and improve outcomes. By removing the requirement for tumor tissue, Latitude™ also improves access to precision monitoring for patients whose tissue is unavailable or insufficient.
Policy Significance
At the policy level, the findings align with healthcare priorities focused on value-based care and precision oncology. Diagnostics that demonstrate strong prognostic and predictive value can reduce overtreatment, optimize resource utilization, and support evidence-based reimbursement decisions. The scale and rigor of the GALAXY dataset provide policymakers and payers with confidence in clinical utility, informing coverage frameworks that incentivize the adoption of validated molecular diagnostics in standard oncology care pathways.
Overall, Natera’s publication validating Latitude™ in colorectal cancer marks a pivotal milestone in tissue-free MRD testing. By demonstrating high sensitivity, specificity, and actionable clinical insights at scale, the study advances regulatory readiness, supports reimbursement pathways, and expands precision-guided care for CRC patients. For the cGxP.wire audience, this development underscores how robust clinical evidence, regulatory alignment, and diagnostic innovation are converging to reshape oncology monitoring and treatment decision-making.
Source: Natera, Inc. press release
